Table 1.

PRESERVE Outcomes

	Name of Outcome	Specific Measure	Timepoints	Powered
Primary	Kidney function decline composite	Composite event of 50% reduction in eGFR, kidney replacement therapy, or eGFR < 15 mL/min/1.73 m2	From CED to end of follow-up	Yes
Secondary	Patient-reported outcome profile	PROMIS Pediatric measures for fatigue, pain, sleep health, anxiety, life satisfaction, and peer relationships Other measures of health status deemed important by parent and youth partners; experience with home BP monitoring	Single time point (date of patient survey)	Yes
Secondary	GFR trajectory	Change in eGFR per unit time	From CED to end of follow-up	Yes
Exploratory	BP treatment adverse events	Diagnosis-based adverse events: hypotension, dizziness, cough, stomatitis, tonsillitis, urinary tract infection, nocturnal enuresis, gastrointestinal symptoms, fatigue, edema, hair loss, respiratory tract infection, pyelonephritis, headache, pericarditis, syncope Laboratory-based adverse events: hyperkalemia, increase in liver enzymes, leukocytopenia, anemia, acidosis Other adverse events: death, ED visit for hypertension, hospitalization for hypertension	From CED to end of follow-up	No

Abbreviations: BP, blood pressure; CED, cohort entrance date; ED, emergency department; eGFR, estimated glomerular filtration rate.